ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
-1.03%
Bitcoin
62,774.93
6.18%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. SpringWorks Therapeutics Inc (SWTX)

  7. SpringWorks Therapeutics Inc (SWTX) Noticias

SWTX SpringWorks Therapeutics Inc

45.11
1.76 (4.06%)
Fuera de horario
Última actualización: 17:00:03
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
SpringWorks Therapeutics Inc SWTX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
1.76 4.06% 45.11 17:00:03
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
44.09 42.12 45.13 45.11 43.35
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
02/5/202405:30GLOBESpringWorks Therapeutics Reports First Quarter 2024..
24/4/202412:31GLOBESpringWorks Therapeutics Announces Abstracts Accepted for..
18/4/202406:00GLOBESpringWorks Therapeutics to Report First Quarter 2024..
04/3/202405:30GLOBESpringWorks Therapeutics Initiates Rolling Submission of New..
01/3/202416:16EDGAR2Form 144 - Report of proposed sale of securities
29/2/202407:30GLOBESpringWorks Therapeutics Announces European Medicines Agency..
27/2/202407:28EDGAR2Form 8-K - Current report
27/2/202407:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27/2/202406:29EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202405:51EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202405:44EDGAR2Form 8-K - Current report
27/2/202405:30GLOBESpringWorks Therapeutics Reports Fourth Quarter and Full..
22/2/202406:00GLOBESpringWorks Therapeutics to Present at Upcoming Investor..
20/2/202417:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202412:09EDGAR2Form 144 - Report of proposed sale of securities
14/2/202407:56EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202420:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202420:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:38EDGAR2Form 144 - Report of proposed sale of securities
02/2/202415:01EDGAR2Form 8-K - Current report
31/1/202406:00GLOBESpringWorks Therapeutics to Participate in the Guggenheim..
08/1/202420:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202420:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202420:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202420:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202420:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202420:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202405:30GLOBESpringWorks Therapeutics Highlights 2023 Accomplishments and..
21/12/202306:00GLOBESpringWorks Therapeutics to Present at the 42nd Annual J.P...
08/12/202315:05GLOBESpringWorks Therapeutics Announces Closing of Upsized Public..
06/12/202315:10EDGAR2Form 8-K - Current report
06/12/202315:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/12/202323:32GLOBESpringWorks Therapeutics Announces Pricing of Upsized Public..
04/12/202315:19EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/12/202315:13GLOBESpringWorks Therapeutics Announces Proposed Public Offering..
29/11/202306:00GLOBESpringWorks Therapeutics to Participate in the 6th Annual..
28/11/202308:00EDGAR2Form 8-K - Current report
28/11/202306:53DJNSpringWorks Shares Rise on FDA Approval for Tumor Treatment
27/11/202317:46DJNSpringWorks Gets FDA Approval for Desmoid Tumor Treatment
27/11/202317:04GLOBESpringWorks Therapeutics Announces FDA Approval of OGSIVEO™..
17/11/202306:00EDGAR2Form 8-K - Current report
16/11/202305:30GLOBESpringWorks Therapeutics Announces Positive Topline Results..
02/11/202320:02EDGAR2Form 144 - Report of proposed sale of securities
02/11/202306:54EDGAR2Form S-3ASR - Automatic shelf registration statement of..
02/11/202305:38EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202305:35EDGAR2Form 8-K - Current report
02/11/202305:30GLOBESpringWorks Therapeutics Reports Third Quarter 2023..
01/11/202305:30GLOBESpringWorks Therapeutics Announces Presentation of..
04/10/202315:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/9/202315:37EDGAR2Form 3 - Initial statement of beneficial ownership of..

Su Consulta Reciente

NASDAQ
SWTX
SpringWorks Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados